The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by FactMR. This remarkable growth potential of the MRI-guided radiation therapy systems market can be attributed to burgeoning adoption of innovative technologies in the cancer diagnosis & treatment, alongside growing focus on patient-centric care.
The study assesses macro and microeconomic factors that define the growth prospects of the MRI-guided radiation therapy systems market. It finds that leading players in the rapidly-growing healthcare sector are vying for new techniques in cancer treatment to compensate for involuntary patient movements and improve precision to a much higher degree. In addition, the paradigm shift in preference of cancer patients towards radiation therapies, from invasive to non-invasive procedures, is expected to remain instrumental in adoption of MRI-guided radiation therapy systems in cancer care.
Hospitals Remain the Target Customers for Market Players
The study opines that hospital, with over 51% revenue share, will remain the target customer for players in the MRI-guided radiation therapy systems market in 2019. Opportunities abound for of MRI-guided radiation therapy system developers, with ongoing clinical development of high-tech procedures exploiting Linac MR-RT (Linear accelerators integrated with magnetic resonance radiotherapy). The study also finds that radiotherapy centers are adopting technologically-advanced MRI-compatible radiation models, to explore numerous possibilities to make radiotherapy treatment more effective. Market players are focusing on building a successful consortium with the help of physicians, clinicians, as well as Original Equipment Manufacturers (OEMs), to tap opportunities in the radiation therapy centers.
Request For a Sample Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=2572
The study opines that the increasing healthcare expenditure in the United States (U.S.) will remain a key growth determinant of the MRI-guided radiation therapy systems market in North America. In 2017, the per capita health expenditure was over US$10,000 in the U.S., recording an increase of nearly 4% over 2016, according to studies. In addition, an alarming rise in the prevalence of cancer in the U.S. will reflect in a significant demand for MRI-guided radiation therapy systems in North America.